Upcoming events – key tests approach for Kadmon and Surface
Kadmon awaits key graft-versus-host disease data, and Surface Oncology's change of tack comes under the spotlight.
Esmo 2018 – Adaptimmune gets the wooden spoon
The company emerges as the worst-performing stock after Europe’s most important cancer conference, which claims numerous other victims.
Astrazeneca asset swap kickstarts Innate's independence
Innate swaps its lead candidate for Astra’s Lumoxiti in a bid to become a rare cancer player.
Gamma-delta follows financing with consolidation
A new cell therapy approach has, in low-key fashion, attracted financing and the attention of big biopharma.
Asco 2018 event analyser – A year of reset expectations
Deciphera Pharmaceuticals emerges as one of the Asco 2018 winner as Jounce Therapeutics falls on weak data.
